About us
Alvolab is a contract research organization specialized in preclinical studies of kidney disease.
Founded in 2023 as a spin-off from Karolinska Institutet, our team brings over 30 years of experience in translational kidney research from leading academic institutions including Harvard Medical School, Karolinska Institutet and Uppsala University, as well as from the pharmaceutical industry.
Our mission is to accelerate the development of novel therapies to treat kidney disease by combining scientific excellence with robust and reproducible preclinical models. To that end, we provide high-quality, cost-effective in vivo and ex vivo models to study acute and chronic kidney disease and diabetic nephropathy.
Animal studies are conducted at an AAALAC-accredited animal research facility affiliated with Karolinska University Hospital.
Based in the Stockholm life sciences ecosystem, our laboratories and offices are located at the Karolinska campus in Solna, close to a broad network of biotechnology and pharmaceutical companies. We have access to state-of-the-art technologies and advanced research platforms, including in vivo imaging, single-cell and bulk RNA sequencing, spatial transcriptomics, proteomics, super-resolution and light-sheet microscopy, as well as AI-assisted data and image analysis.
M.D., Ph.D., CEO
Board-certified pathologist at Karolinska University Hospital and principal investigator with 15 years of experience in preclinical kidney disease research from Karolinska Institutet and Harvard Medical School. Leads and participates in several European and national preclinical kidney disease research projects.
LinkedIn profile →M.D., Ph.D., Principal Scientist
Over 20 years of experience in preclinical research, from both academia (Uppsala University and Karolinska Institutet) and the pharmaceutical industry (Guard Therapeutics), with deep expertise in preclinical models of kidney disease.
LinkedIn profile →Ph.D., Principal Scientist
Over 20 years of experience in biomedical and preclinical research at leading institutions in Sweden, China, and the United States, with extensive expertise in cardiovascular research. He has successfully led multiple research projects, with findings published in leading international scientific journals.
LinkedIn profile →Tell us about your compound and your target indication, and we will propose a study design with the models and readouts that fit your programme.